PTC receives $25 million from CFFT
This article was originally published in Scrip
PTC Therapeuticsis to receive further financial support from Cystic Fibrosis Foundation Therapeutics(CFFT), the non-profit subsidiary of the Cystic Fibrosis Foundation, to support development of PTC124, PTC's investigational oral drug for cystic fibrosis caused by nonsense mutations. PTC will receive up to $25 million to fund Phase IIb clinical trials of PTC124. In 2005, it received $1.7 million from CFFT to fund the Phase I trials. Last month, PTC reported data from Phase IIa studies of PTC124 in adult and paediatric cystic fibrosis patients demonstrating significant improvements in the primary outcome measure – nasal potential difference. A three-month, Phase IIa extension study of adult patients showed a significant mean decrease in the frequency of cough, one of the most prominent symptoms of the disease. PTC124 is also in Phase IIb development for Duchenne muscular dystrophy.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.